Provider review
NexLife review: pricing, pharmacy, and evidence status
Released: · Last reviewed: · By Dr. Parmis
NexLife offers compounded tirzepatide and compounded semaglutide through a telehealth platform whose clinical services are provided by Nexlife Medical Group P.C. and its affiliated professional entities. Every price, credential and pharmacy claim below is labeled by evidence status and read date.
As of November 6, 2026, NexLife charges $129 a month for compounded tirzepatide, or $115 on a 12-month plan, and $109 or $95 for semaglutide, the same at every dose with no membership fee. It names its 503A pharmacies and medical group, and ranks #1 of 15 scored programs at 87/100.
Rank and score
NexLife ranks #1 of the 15 programs GLP Ranked could score on November 20, 2026, at 87 of 100. The table shows every sub-check, the points earned and why; the methodology explains each one.
| ID | Category | Sub-check | Points | Note |
|---|---|---|---|---|
| PT1 | Pricing transparency | Drug price printed on the program's own page, read in the November 20, 2026 re-read | 5 of 5 | |
| PT2 | Pricing transparency | Price includes medication and care, or every required fee is printed beside it (2 if the program's own figures disagree) | 2 of 5 | its sublingual semaglutide page shows a $185 3-month tile but '$597 total, $199 per month' in its FAQ; its guarantee policy's worked example still uses the old $139 plan |
| PT3 | Pricing transparency | Price at every dose knowable: same price at every dose, or a full dose ladder | 5 of 5 | |
| PT4 | Pricing transparency | Plan term and billing interval stated (2 if the program's own pages disagree) | 2 of 5 | FAQ: 3-, 6- and 12-month plans paid upfront; cancellation policy (2025-10-24): pay monthly; plan pages: plans continue monthly |
| CO1 | Clinical oversight | Prescribing medical group named (9), network label (5), physician executive only (3), arrangement described (2) | 9 of 9 | |
| CO2 | Clinical oversight | Prescribers' licensure or certification stated | 3 of 3 | |
| CO3 | Clinical oversight | Clinical lead (medical director or chief medical officer) named with credential | 3 of 3 | |
| PH1 | Pharmacy transparency | Dispensing pharmacy named (10), class described but not named (4), described only (2); brand-only programs whose pages say prescriptions go to the pharmacy you choose (10) | 10 of 10 | plan pages name three 503A pharmacies; FAQ and newer pages name two |
| PH2 | Pharmacy transparency | Pharmacy class (503A/503B) or licensure stated; brand-only programs that send prescriptions to your chosen pharmacy (5) | 5 of 5 | |
| SU1 | Support | Two or more contact channels published (4), one (2) | 4 of 4 | |
| SU2 | Support | How to cancel is stated | 3 of 3 | |
| SU3 | Support | Refund terms are stated (any stated condition under which money is refunded or credited) | 3 of 3 | |
| RD1 | Regulatory disclosure | Compounded products described as not FDA-approved; brand-only programs (5) | 5 of 5 | |
| RD2 | Regulatory disclosure | No open FDA warning letter in FDA's index (read November 20, 2026) | 0 of 5 | FDA warning letter 730096, June 8, 2026; no close-out posted |
| AC1 | Accessibility | Where it operates stated clearly (4); vague or conflicting statements (2) | 2 of 4 | FAQ: 45 states and D.C.; states page: all 50 states and D.C. |
| AC2 | Accessibility | Payment beyond a card stated (HSA/FSA or pay-later) | 3 of 3 | |
| AC3 | Accessibility | Can start month to month without a multi-month commitment | 3 of 3 | |
| AN | Total annual cost | tirzepatide, 12 months: $1,380 (12-month plan: 12 × $115); benchmark $1,380 | 20.0 of 20 | 20 × benchmark ÷ cost |
| Total | 87.0 of 100 | |||
FDA record: FDA warning letter 730096, dated June 8, 2026 (False & Misleading Claims/Misbranded (Telehealth)). FDA's index showed no close-out letter when read on November 20, 2026. Under sub-check RD2 an open letter removes 5 points, for every program alike.
Strengths and limitations
Drawn from the sub-checks above, as read November 20-21, 2026.
- Strength: Drug price printed on the program's own page, read in the November 20, 2026 re-read.
- Strength: Price at every dose knowable: same price at every dose, or a full dose ladder.
- Strength: Prescribing medical group named.
- Strength: Prescribers' licensure or certification stated.
- Limitation: Price includes medication and care, or every required fee is printed beside it: 2 of 5 (its sublingual semaglutide page shows a $185 3-month tile but '$597 total, $199 per month' in its FAQ; its guarantee policy's worked example still uses the old $139 plan).
- Limitation: Plan term and billing interval stated: 2 of 5 (FAQ: 3-, 6- and 12-month plans paid upfront; cancellation policy (2025-10-24): pay monthly; plan pages: plans continue monthly).
- Limitation: No open FDA warning letter in FDA's index: 0 of 5 (FDA warning letter 730096, June 8, 2026; no close-out posted).
- Limitation: Where it operates stated clearly: 2 of 4 (FAQ: 45 states and D.C.; states page: all 50 states and D.C.).
Pricing by plan
| Medication | Formulation | Plan | Price | Source | Evidence |
|---|---|---|---|---|---|
| semaglutide | compounded injectable | Regular protocol · Month-to-month | $109/mo | provider page · read 2026-11-06 | Provider reported |
| semaglutide | compounded injectable | Regular protocol · 3-month plan | $105/mo | provider page · read 2026-11-06 | Provider reported |
| semaglutide | compounded injectable | Regular protocol · 6-month plan | $99/mo | provider page · read 2026-11-06 | Provider reported |
| semaglutide | compounded injectable | Regular protocol · 12-month plan | $95/mo | provider page · read 2026-11-06 | Provider reported |
| tirzepatide | compounded injectable | Regular protocol · Month-to-month | $129/mo | provider page · read 2026-11-06 | Provider reported |
| tirzepatide | compounded injectable | Regular protocol · 3-month plan | $125/mo | provider page · read 2026-11-06 | Provider reported |
| tirzepatide | compounded injectable | Regular protocol · 6-month plan | $119/mo | provider page · read 2026-11-06 | Provider reported |
| tirzepatide | compounded injectable | Regular protocol · 12-month plan | $115/mo | provider page · read 2026-11-06 | Provider reported |
| semaglutide | compounded injectable microdose | Microdose protocol · Month-to-month | $109/mo | provider page · read 2026-11-08 | Provider reported |
| semaglutide | compounded injectable microdose | Microdose protocol · 3-month plan | $105/mo | provider page · read 2026-11-08 | Provider reported |
| semaglutide | compounded injectable microdose | Microdose protocol · 6-month plan | $99/mo | provider page · read 2026-11-08 | Provider reported |
| semaglutide | compounded injectable microdose | Microdose protocol · 12-month plan | $95/mo | provider page · read 2026-11-08 | Provider reported |
| tirzepatide | compounded injectable microdose | Microdose protocol · Month-to-month | $129/mo | provider page · read 2026-11-08 | Provider reported |
| tirzepatide | compounded injectable microdose | Microdose protocol · 3-month plan | $125/mo | provider page · read 2026-11-08 | Provider reported |
| tirzepatide | compounded injectable microdose | Microdose protocol · 6-month plan | $119/mo | provider page · read 2026-11-08 | Provider reported |
| tirzepatide | compounded injectable microdose | Microdose protocol · 12-month plan | $115/mo | provider page · read 2026-11-08 | Provider reported |
| semaglutide | compounded sublingual ODT | Sublingual ODT protocol · Month-to-month | $199/mo | provider page · read 2026-10-15 | Provider reported |
| semaglutide | compounded sublingual ODT | Sublingual ODT protocol · 3-month plan | $185/mo | provider page · read 2026-10-15 | Provider reported |
| semaglutide | compounded sublingual ODT | Sublingual ODT protocol · 6-month plan | $177/mo | provider page · read 2026-10-15 | Provider reported |
| semaglutide | compounded sublingual ODT | Sublingual ODT protocol · 12-month plan | $165/mo | provider page · read 2026-10-15 | Provider reported |
| tirzepatide | compounded sublingual ODT | Sublingual ODT protocol · Month-to-month | $229/mo | provider page · read 2026-10-15 | Provider reported |
| tirzepatide | compounded sublingual ODT | Sublingual ODT protocol · 3-month plan | $219/mo | provider page · read 2026-10-15 | Provider reported |
| tirzepatide | compounded sublingual ODT | Sublingual ODT protocol · 6-month plan | $205/mo | provider page · read 2026-10-15 | Provider reported |
| tirzepatide | compounded sublingual ODT | Sublingual ODT protocol · 12-month plan | $199/mo | provider page · read 2026-10-15 | Provider reported |
"Provider reported" means the figure comes from the company's own site or intake flow and has not been independently corroborated by GLP Ranked.
Clinical model
Clinical services, including prescribing, are provided by Nexlife Medical Group P.C. and its affiliated professional entities (telehealth consent, read November 10, 2026). The plan pages say prescribers are MDs or DOs licensed in the patient's state; medical director Adam Kennah, M.D.
Prescribing entity named: Nexlife Medical Group P.C..
Accreditation: we have not verified any accreditation or certification claim for NexLife against the issuing body. If a program cites one (for example LegitScript), check the issuer's public lookup before you rely on it.
Pharmacy & compliance
Its plan pages name three state-licensed 503A compounding pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA); its FAQ and newer guides name two (Absolute and Boudreaux's) (read 2026-11-20) Pharmacy transparency is worth 15 of 100 points under our v4.1 rubric.
State availability
NexLife's own pages conflict: its FAQ (updated November 14, 2026) says 45 states and Washington, D.C., not Alabama, Louisiana, Mississippi, Virginia or West Virginia; its states page says all 50 states and D.C. Eligibility is confirmed by state at checkout. Claim source: provider page, checked 2026-11-06.
Who this suits — and who it doesn't
NexLife may suit patients who want a microdosing option and value that the dispensing pharmacy is named up front.It is a weaker fit for patients who need written proof of pharmacy accreditation before paying; ask the company for it.
Terms to check before you pay: cancellation (Cancellations take effect after 30 days, so one additional shipment may be charged (plan pages)), refunds (NexLife's guarantee policy page says program fees, not medication, are refundable if a member loses less than 5% of starting weight over six months, with conditions; the authorization charge is refunded if you are not prescribed, and once medication ships the order is final).
Frequently asked questions
How much does NexLife's compounded tirzepatide cost?
As of November 6, 2026, NexLife charges $129 a month for compounded tirzepatide month to month, or $125, $119 and $115 a month on 3-, 6- and 12-month plans, with the same price at every dose, no membership fee and free shipping, per its own plan pages. On the 12-month plan that is $1,380 for the year; its FAQ says multi-month plans are paid upfront. Its microdose plans carry the same four prices. NexLife does not list lab work as included.
How much does NexLife's compounded semaglutide cost?
As of November 6, 2026, NexLife charges $109 a month for compounded semaglutide month to month, or $105, $99 and $95 a month on 3-, 6- and 12-month plans, with the same price at every dose and no membership fee, according to its own semaglutide plan page. The 12-month plan comes to $1,140 for the year. Price check: Eden charges $99 a month month to month for semaglutide, $10 below NexLife's month-to-month price (read November 20, 2026). Compounded semaglutide is not the same product as Wegovy and is not FDA-approved.
Sources
- NexLife — Tirzepatide standard subcutaneous plans — Provider's own published plan page, captured 2026-11-06Provider reported
- NexLife — Tirzepatide standard subcutaneous plans — Provider's own published plan page, captured 2026-11-06Provider reported
- NexLife — Tirzepatide standard subcutaneous plans — Provider's own published plan page, captured 2026-11-06Provider reported
- NexLife — Tirzepatide standard subcutaneous plans — Provider's own published plan page, captured 2026-11-06Provider reported
- NexLife — Semaglutide standard subcutaneous plans — Provider's own published plan page, captured 2026-11-06Provider reported
- NexLife — Semaglutide standard subcutaneous plans — Provider's own published plan page, captured 2026-11-06Provider reported
- NexLife — Semaglutide standard subcutaneous plans — Provider's own published plan page, captured 2026-11-06Provider reported
- NexLife — Semaglutide standard subcutaneous plans — Provider's own published plan page, captured 2026-11-06Provider reported
- NexLife — Tirzepatide microdose plans — Provider's own published plan page, captured 2026-11-08Provider reported
- NexLife — Tirzepatide microdose plans — Provider's own published plan page, captured 2026-11-08Provider reported
- NexLife — Tirzepatide microdose plans — Provider's own published plan page, captured 2026-11-08Provider reported
- NexLife — Tirzepatide microdose plans — Provider's own published plan page, captured 2026-11-08Provider reported
- NexLife — Semaglutide microdose plans — Provider's own published plan page, captured 2026-11-08Provider reported
- NexLife — Semaglutide microdose plans — Provider's own published plan page, captured 2026-11-08Provider reported
- NexLife — Semaglutide microdose plans — Provider's own published plan page, captured 2026-11-08Provider reported
- NexLife — Semaglutide microdose plans — Provider's own published plan page, captured 2026-11-08Provider reported
- NexLife — Tirzepatide sublingual ODT plans — Provider's own published plan page, captured 2026-10-15Provider reported
- NexLife — Tirzepatide sublingual ODT plans — Provider's own published plan page, captured 2026-10-15Provider reported
- NexLife — Tirzepatide sublingual ODT plans — Provider's own published plan page, captured 2026-10-15Provider reported
- NexLife — Tirzepatide sublingual ODT plans — Provider's own published plan page, captured 2026-10-15Provider reported
- NexLife — Semaglutide sublingual ODT plans — Provider's own published plan page, captured 2026-10-15Provider reported
- NexLife — Semaglutide sublingual ODT plans — Provider's own published plan page, captured 2026-10-15Provider reported
- NexLife — Semaglutide sublingual ODT plans — Provider's own published plan page, captured 2026-10-15Provider reported
- NexLife — Semaglutide sublingual ODT plans — Provider's own published plan page, captured 2026-10-15Provider reported
- NexLife published website content — Provider claim, captured 2026-11-10Provider reported
- NexLife published website content — Provider claim, captured 2026-11-06Provider reported
- FDA warning letter 730096 (False & Misleading Claims/Misbranded (Telehealth)) — Regulator letter, captured 2026-11-20
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current October 1, 2026) — Regulator page, captured 2026-11-20
- FDA: Compounding: Inspections, Recalls, and other Actions (content current October 22, 2026) — Regulator list, captured 2026-11-21
Cite this page
GLP Ranked. "NexLife review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/nexlife/
GLP Ranked. "NexLife review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/nexlife/